FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281907835> ?p ?o ?g. }

• W4281907835 endingPage "1035" @default.
• W4281907835 startingPage "1035" @default.
• W4281907835 abstract "1035 Background: For human epidermal growth factor receptor 2 (HER2) positive advanced or metastatic breast cancer, the standard therapeutic strategy is HER2-targeted agents combined with a taxane. This multicenter, single-arm phase 2 trial was designed to assess the efficacy and safety of pyrotinib (a brand-new generation, irreversible anti-HER2 tyrosine kinase inhibitor) plus nab-paclitaxel in patients with HER2-positive advanced or metastatic breast cancer. Methods: This was a multicenter, single-arm, open-label phase 2 trial conducted at seven centers in China (ChiCTR1900023653). Women aged 18-75 years, with histologically or cytologically confirmed HER-2 positive (immunohistochemistry [IHC] 3+ or positive confirmed by fluorescence in situ hybridization) advanced or metastatic breast cancer and with Eastern Cooperative Oncology Group performance score (ECOG PS) of 0-1 were enrolled. Patients with primary resistance to trastuzumab and bone-only metastases were excluded. Eligible patients received pyrotinib (400 mg, po, qd) plus nab-paclitaxel (125 mg/m 2 , iv, day 1/8/15) for each 28-day cycle until disease progression, unacceptable toxicity, consent withdrawal or death. The primary endpoint was objective response rate (ORR), defined as the proportion of patients with complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary endpoints included progression-free survival (PFS), overall survival, safety and quality of life. Results: Between December 2019 and December 2021, 51 patients were enrolled. The median age was 55 years (range 35–72). Twenty-three patients (45.1%) had ECOG PS of 0. Ten patients (19.6%) with metastatic disease had previously received first-line treatment and 28 (54.9%) had received prior treatment with trastuzumab. More than half (29 of 51, 56.9%) had hormone receptor-positive disease. Visceral metastases occurred in 56.9% of the patients (29 of 51) and 26 patients (51.0%) were menopausal. The data cutoff for the present analysis was January 21, 2022. Among 38 evaluable patients, four patients (10.5%) had CR, 27 (71.1%) had PR, six (15.8%) had stable disease, and one (2.6%) had progressive disease. The confirmed ORR was 81.6% (95% CI 65.1-91.7%). The PFS data were still immature. The most common grade ≥3 treatment-emergent adverse events included neutropenia (14 of 51, 27.5%), diarrhea (10 of 51, 19.6%), fatigue (5 of 51, 9.8%) and peripheral neuropathy (4 of 51, 7.8%). Conclusions: Pyrotinib combined with nab-paclitaxel showed a promising antitumor activity with good tolerance in patients with HER2-positive advanced or metastatic breast cancer. Clinical trial information: ChiCTR1900023653." @default.
• W4281907835 created "2022-06-13" @default.
• W4281907835 creator A5000650768 @default.
• W4281907835 creator A5001014826 @default.
• W4281907835 creator A5003642180 @default.
• W4281907835 creator A5015595184 @default.
• W4281907835 creator A5017379979 @default.
• W4281907835 creator A5023104270 @default.
• W4281907835 creator A5023179237 @default.
• W4281907835 creator A5023694096 @default.
• W4281907835 creator A5035762225 @default.
• W4281907835 creator A5036291399 @default.
• W4281907835 creator A5036354698 @default.
• W4281907835 creator A5044743726 @default.
• W4281907835 creator A5047054725 @default.
• W4281907835 creator A5049431654 @default.
• W4281907835 creator A5052721468 @default.
• W4281907835 creator A5056948476 @default.
• W4281907835 creator A5057085664 @default.
• W4281907835 creator A5057114375 @default.
• W4281907835 creator A5076176073 @default.
• W4281907835 creator A5081708560 @default.
• W4281907835 date "2022-06-01" @default.
• W4281907835 modified "2023-10-17" @default.
• W4281907835 title "Pyrotinib plus nab-paclitaxel in patients with HER2-positive advanced or metastatic breast cancer: A multicenter, single-arm, open-label phase 2 trial." @default.
• W4281907835 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.1035" @default.
• W4281907835 hasPublicationYear "2022" @default.
• W4281907835 type Work @default.
• W4281907835 citedByCount "0" @default.
• W4281907835 crossrefType "journal-article" @default.
• W4281907835 hasAuthorship W4281907835A5000650768 @default.
• W4281907835 hasAuthorship W4281907835A5001014826 @default.
• W4281907835 hasAuthorship W4281907835A5003642180 @default.
• W4281907835 hasAuthorship W4281907835A5015595184 @default.
• W4281907835 hasAuthorship W4281907835A5017379979 @default.
• W4281907835 hasAuthorship W4281907835A5023104270 @default.
• W4281907835 hasAuthorship W4281907835A5023179237 @default.
• W4281907835 hasAuthorship W4281907835A5023694096 @default.
• W4281907835 hasAuthorship W4281907835A5035762225 @default.
• W4281907835 hasAuthorship W4281907835A5036291399 @default.
• W4281907835 hasAuthorship W4281907835A5036354698 @default.
• W4281907835 hasAuthorship W4281907835A5044743726 @default.
• W4281907835 hasAuthorship W4281907835A5047054725 @default.
• W4281907835 hasAuthorship W4281907835A5049431654 @default.
• W4281907835 hasAuthorship W4281907835A5052721468 @default.
• W4281907835 hasAuthorship W4281907835A5056948476 @default.
• W4281907835 hasAuthorship W4281907835A5057085664 @default.
• W4281907835 hasAuthorship W4281907835A5057114375 @default.
• W4281907835 hasAuthorship W4281907835A5076176073 @default.
• W4281907835 hasAuthorship W4281907835A5081708560 @default.
• W4281907835 hasConcept C121608353 @default.
• W4281907835 hasConcept C126322002 @default.
• W4281907835 hasConcept C141071460 @default.
• W4281907835 hasConcept C143998085 @default.
• W4281907835 hasConcept C203092338 @default.
• W4281907835 hasConcept C2775930923 @default.
• W4281907835 hasConcept C2776694085 @default.
• W4281907835 hasConcept C2777511904 @default.
• W4281907835 hasConcept C2778822529 @default.
• W4281907835 hasConcept C2779786085 @default.
• W4281907835 hasConcept C2779984678 @default.
• W4281907835 hasConcept C2780739268 @default.
• W4281907835 hasConcept C31760486 @default.
• W4281907835 hasConcept C530470458 @default.
• W4281907835 hasConcept C535046627 @default.
• W4281907835 hasConcept C71924100 @default.
• W4281907835 hasConceptScore W4281907835C121608353 @default.
• W4281907835 hasConceptScore W4281907835C126322002 @default.
• W4281907835 hasConceptScore W4281907835C141071460 @default.
• W4281907835 hasConceptScore W4281907835C143998085 @default.
• W4281907835 hasConceptScore W4281907835C203092338 @default.
• W4281907835 hasConceptScore W4281907835C2775930923 @default.
• W4281907835 hasConceptScore W4281907835C2776694085 @default.
• W4281907835 hasConceptScore W4281907835C2777511904 @default.
• W4281907835 hasConceptScore W4281907835C2778822529 @default.
• W4281907835 hasConceptScore W4281907835C2779786085 @default.
• W4281907835 hasConceptScore W4281907835C2779984678 @default.
• W4281907835 hasConceptScore W4281907835C2780739268 @default.
• W4281907835 hasConceptScore W4281907835C31760486 @default.
• W4281907835 hasConceptScore W4281907835C530470458 @default.
• W4281907835 hasConceptScore W4281907835C535046627 @default.
• W4281907835 hasConceptScore W4281907835C71924100 @default.
• W4281907835 hasFunder F4320318394 @default.
• W4281907835 hasIssue "16_suppl" @default.
• W4281907835 hasLocation W42819078351 @default.
• W4281907835 hasOpenAccess W4281907835 @default.
• W4281907835 hasPrimaryLocation W42819078351 @default.
• W4281907835 hasRelatedWork W1991102770 @default.
• W4281907835 hasRelatedWork W2161579354 @default.
• W4281907835 hasRelatedWork W2406128178 @default.
• W4281907835 hasRelatedWork W2517194109 @default.
• W4281907835 hasRelatedWork W2592387149 @default.
• W4281907835 hasRelatedWork W3177425057 @default.
• W4281907835 hasRelatedWork W4220700928 @default.
• W4281907835 hasRelatedWork W4281907835 @default.
• W4281907835 hasRelatedWork W4286295233 @default.
• W4281907835 hasRelatedWork W4304690509 @default.
• W4281907835 hasVolume "40" @default.

• next